Paul Hartmann AG (PHH2.F)
- Previous Close
255.00 - Open
251.00 - Bid 251.00 x 3200
- Ask 255.00 x 10000
- Day's Range
251.00 - 251.00 - 52 Week Range
183.00 - 255.00 - Volume
85 - Avg. Volume
73 - Market Cap (intraday)
891.487M - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
8.22 - EPS (TTM)
30.52 - Earnings Date Apr 28, 2025 - May 2, 2025
- Forward Dividend & Yield 8.00 (3.14%)
- Ex-Dividend Date May 2, 2025
- 1y Target Est
--
Paul Hartmann AG manufactures and sells medical and care products in Germany, rest of Europe, the Middle East, Africa, Asia and Pacific region, and the Americas. The company operates through three segments: Incontinence Management, Wound Care, and Infection Management. It offers body-absorbent products and traditional and modern wound dressings. In addition, the company produce single-use products and solutions for infection; hand, surface, and instrument disinfection; and cleaning, skin care, and skin antisepsis. Further, it offers Link, a platform to learn and exchange medical and clinical knowledge. It sells its products through pharmacies, medical supply stores, and online channels. The company was founded in 1818 and is headquartered in Heidenheim, Germany.
hartmann.info10,079
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: PHH2.F
View More
Performance Overview: PHH2.F
Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHH2.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHH2.F
View MoreValuation Measures
Market Cap
905.69M
Enterprise Value
1.03B
Trailing P/E
8.35
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.38
Price/Book (mrq)
0.79
Enterprise Value/Revenue
0.43
Enterprise Value/EBITDA
4.16
Financial Highlights
Profitability and Income Statement
Profit Margin
4.47%
Return on Assets (ttm)
3.32%
Return on Equity (ttm)
9.84%
Revenue (ttm)
2.43B
Net Income Avi to Common (ttm)
108.45M
Diluted EPS (ttm)
30.52
Balance Sheet and Cash Flow
Total Cash (mrq)
160.91M
Total Debt/Equity (mrq)
24.54%
Levered Free Cash Flow (ttm)
-34.24M